A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer

AstraZeneca56 enrolled

Overview

The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Small Cell Lung Cancer

Interventions

GefitinibDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of written informed consent * Histologically confirmed, relapsed or refractory SCLCr * Aged 18 or over and a life expectancy of more than 2 months Exclusion Criteria: * Any evidence of clinically active interstitial lung disease * Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ.

Locations (3)

Research Site

Copenhagen, Denmark

Research Site

Herlev, Denmark

Research Site

Manchester, United Kingdom

Outcomes

Primary Outcomes

To determine the disease control rate in these patients

Secondary Outcomes

To determine the objective response rate at trail closure in these patients

To determine the time to progression-or-death in these patients

To determine overall survival in these patients

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.